Details der Publikation - Uno studio per valutare l'efficacia e la sicurezza del farmaco in studio, quando ai pazienti ¿ dato un dosaggio di 200 mcg di IPP-201101 pi¿ standard di cura, in pazienti con lupus eritematoso sistemico.

Uno studio per valutare l'efficacia e la sicurezza del farmaco in studio, quando ai pazienti ¿ dato un dosaggio di 200 mcg di IPP-201101 pi¿ standard di cura, in pazienti con lupus eritematoso sistemico. : A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus - A study to evaluate the effectiveness and safety of the study drug for patients with SLE.

Medienart:	Klinische Studie

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	WHO International Clinical Trials Registry Platform - (2022) vom: 14. März Zur Gesamtaufnahme - year:2022

Sprache:	Italienisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Systemic Lupus Erythematosus MedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12] Phase: Phase 3 Recruitment Status: Not yet recruiting Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 19-01-2021, Last updated: 2022-11-24

ICTRP ID:	EUCTR2015-003341-25-IT IPP-201101/005 2015-003341-25-HU

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO007813112

Internformat


LEADER	01000caa a22002652 4500
001	WHO007813112
003	DE-627
005	20230425171259.0
007	cr uuu---uuuuu
008	210818s2022 xx \|\|\|\|\|o 00\| \|\|ita c
035			\|a (DE-627)WHO007813112
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2015-003341-25-IT
035			\|a (UBBS_Klinische_Studien_WHO)IPP-201101/005
035			\|a (UBBS_Klinische_Studien_WHO)2015-003341-25-HU
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a ita
245	1	0	\|a Uno studio per valutare l'efficacia e la sicurezza del farmaco in studio, quando ai pazienti ¿ dato un dosaggio di 200 mcg di IPP-201101 pi¿ standard di cura, in pazienti con lupus eritematoso sistemico. \|b A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus - A study to evaluate the effectiveness and safety of the study drug for patients with SLE.
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 19-01-2021, Last updated: 2022-11-24
650		4	\|a Medical Condition: Systemic Lupus Erythematosus MedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Not yet recruiting
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2022) vom: 14. März
773	1	8	\|g year:2022 \|g day:14 \|g month:03
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003341-25 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2022 \|b 14 \|c 03

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände